Skip to content

Study · Animal study (in vivo) · rat · 2009

3 results

A functional melanocortin system may be required for chronic CNS-mediated antidiabetic and cardiovascular actions of leptin.

da Silva AA, do Carmo JM, Freeman JN, Tallam LS, Hall JE

Diabetes2 Jun 2009Cited by 45 (Europe PMC)

PMID19491210 (opens in a new tab)PMCIDPMC2712780 (opens in a new tab)DOI10.2337/db08-1221 (opens in a new tab)PepBankPUB-19491210
Read at sourcePubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC-ND. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, intracerebroventricular MTII infusion transiently reduced blood glucose; values returned to diabetic levels after 5-7 days.

    In plain wordsIn diabetic rats, MTII infused into the brain lowered blood glucose only for a short time.

    Peptide
    Melanotan II
    Outcome
    DecreaseBlood glucose
    Study

    ratn: not reported in source

    in vivo, streptozotocin diabetic Sprague-Dawley rats
    Outcome group
    Glycemic control · Metabolic and weight
    Studied dose
    10 ng/h, then 50 ng/h · intracerebroventricular infusion · 12 days at 10 ng/h, then 7 days at 50 ng/hAs given in this study (rat).

    Source sentences

    Summary
    MTII infusions transiently reduced blood glucose and raised heart rate and MAP, which returned to diabetic values 5-7 days after starting the infusion.
    2 context sentences
    Summary · context
    After recovery from surgery for 8 days, rats were injected with streptozotocin (STZ), and 5 days later, either saline or the melanocortin 3 and 4 receptor (MC3/4R) antagonist SHU-9119 (1 nmol/h) was infused intracerebroventricularly for 17 days.
    Summary · context
    Another group of diabetic rats was infused with the MC3/4R agonist MTII (10 ng/h i.c.v.) for 12 days, followed by 7 days at 50 ng/h.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, intracerebroventricular MTII infusion transiently raised heart rate; values returned to diabetic levels after 5-7 days.

    In plain wordsIn diabetic rats, MTII infused into the brain raised heart rate only for a short time.

    Peptide
    Melanotan II
    Outcome
    IncreaseHeart rate
    Study

    ratn: not reported in source

    in vivo, streptozotocin diabetic Sprague-Dawley rats
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    10 ng/h, then 50 ng/h · intracerebroventricular infusion · 12 days at 10 ng/h, then 7 days at 50 ng/hAs given in this study (rat).

    Source sentences

    Summary
    MTII infusions transiently reduced blood glucose and raised heart rate and MAP, which returned to diabetic values 5-7 days after starting the infusion.
    2 context sentences
    Summary · context
    After recovery from surgery for 8 days, rats were injected with streptozotocin (STZ), and 5 days later, either saline or the melanocortin 3 and 4 receptor (MC3/4R) antagonist SHU-9119 (1 nmol/h) was infused intracerebroventricularly for 17 days.
    Summary · context
    Another group of diabetic rats was infused with the MC3/4R agonist MTII (10 ng/h i.c.v.) for 12 days, followed by 7 days at 50 ng/h.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In diabetic rats, intracerebroventricular MTII infusion transiently raised mean arterial pressure; values returned to diabetic levels after 5-7 days.

    In plain wordsIn diabetic rats, MTII infused into the brain raised blood pressure only for a short time.

    Peptide
    Melanotan II
    Outcome
    IncreaseMean arterial pressure
    Study

    ratn: not reported in source

    in vivo, streptozotocin diabetic Sprague-Dawley rats
    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    10 ng/h, then 50 ng/h · intracerebroventricular infusion · 12 days at 10 ng/h, then 7 days at 50 ng/hAs given in this study (rat).

    Source sentences

    Summary
    MTII infusions transiently reduced blood glucose and raised heart rate and MAP, which returned to diabetic values 5-7 days after starting the infusion.
    2 context sentences
    Summary · context
    After recovery from surgery for 8 days, rats were injected with streptozotocin (STZ), and 5 days later, either saline or the melanocortin 3 and 4 receptor (MC3/4R) antagonist SHU-9119 (1 nmol/h) was infused intracerebroventricularly for 17 days.
    Summary · context
    Another group of diabetic rats was infused with the MC3/4R agonist MTII (10 ng/h i.c.v.) for 12 days, followed by 7 days at 50 ng/h.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 09:43 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.